Octimet Oncology Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Octimet Oncology General Information

Description

Developer of discovery-stage molecules designed to treat cancer cells. The company's molecules include cMET inhibitors and other highly selective anti-tumor molecules by employing patient selection, pharmacodynamic biomarker-based strategies, and clinical development approaches to provide differentiation both within the current treatment paradigms and from competitor agents using biotechnological therapeutics, enabling patients to get treatment for cancer.

Contact Information

Website
www.octimet.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Pieter Van Reysschootlaan 2/104
  • Sint-Denijs-Westrem
  • 9051 Ghent
  • Belgium
+32
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Pieter Van Reysschootlaan 2/104
  • Sint-Denijs-Westrem
  • 9051 Ghent
  • Belgium
+32

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Octimet Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Jan-2022 Completed Generating Revenue
3. Grant 08-Aug-2018 Completed Generating Revenue
2. Grant 09-Nov-2017 $1.31M $11.9M Completed Generating Revenue
1. Early Stage VC (Series A) 18-Jan-2017 $11.9M $11.9M Completed Generating Revenue
To view Octimet Oncology’s complete valuation and funding history, request access »

Octimet Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class A2
Class A1
Class A2 50,694 $9.58 $9.58 1x $9.58 8.42%
To view Octimet Oncology’s complete cap table history, request access »

Octimet Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Octimet Oncology Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
VLAIO Limited Partner
To view Octimet Oncology’s complete investors history, request access »

Octimet Oncology FAQs

  • When was Octimet Oncology founded?

    Octimet Oncology was founded in 2016.

  • Where is Octimet Oncology headquartered?

    Octimet Oncology is headquartered in Ghent, Belgium.

  • What is the size of Octimet Oncology?

    Octimet Oncology has 5 total employees.

  • What industry is Octimet Oncology in?

    Octimet Oncology’s primary industry is Drug Discovery.

  • Is Octimet Oncology a private or public company?

    Octimet Oncology is a Private company.

  • What is Octimet Oncology’s current revenue?

    The current revenue for Octimet Oncology is .

  • How much funding has Octimet Oncology raised over time?

    Octimet Oncology has raised $11.9M.

  • Who are Octimet Oncology’s investors?

    VLAIO has invested in Octimet Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process